follow
discoveryi
nt
niclosamid
figur
initi
use
olluscicid
kill
snail
around
ad
ecadel
ater
tw
found
effect
human
tapeworm
infect
use
human
treat
tapeworm
infectionss
tartedi
ollow
approv
us
food
drug
administr
fda
sinc
world
health
organ
essenti
listo
fm
edicin
structur
n
iclosamid
belong
al
arg
group
lipophil
weakli
acid
molecul
call
salicylanilid
figur
despit
wide
use
anthelminticdrug
mechan
action
niclosamid
yet
complet
understood
earli
studi
link
niclosamid
activ
uncoupl
oxid
phosphoryl
howev
ver
last
decadeo
rs
niclosamid
shown
act
target
wntbcatenin
mtor
signal
pathway
review
chen
et
al
inevit
link
niclosamid
therapeut
potentialt
om
diseas
involv
import
signal
cascadest
increas
interest
niclosamid
last
decadei
sr
eflect
significanti
ncreas
number
public
regard
studi
drug
figur
herein
briefli
discuss
numer
diseas
niclosamid
shown
promis
treat
pharmacolog
activ
niclosamid
parkinsonsd
iseas
pd
mutat
impairt
catalyt
activ
mitochondri
serinethreonin
protein
kinasep
pteninduc
kinas
found
cause
arli
onset
pd
neuron
apoptosi
becam
appar
small
molecul
activ
would
neuroprotect
effect
thu
potentialt
ot
reat
pd
equip
fact
activ
mitochondri
depolar
barini
et
al
investig
whether
niclosamid
known
caus
mitochondri
depolar
could
activ
result
showedt
hat
niclosamid
ap
otent
activ
cell
studi
showedt
hat
niclosamid
ad
irect
activ
activ
observ
recombin
incub
vitro
howev
tw
shown
niclosamid
causedm
itochondri
depolar
phenomenon
foundt
ob
erevers
follow
remov
niclosamid
cell
media
impress
niclosamid
also
shown
activ
nc
ultur
neuron
niclosamid
anthelmint
drug
use
year
mainli
treat
tapeworm
infect
howev
increasei
nd
rug
repurpos
initi
niclosamid
emerg
rue
hit
mani
screen
variou
diseas
inde
anthelmint
drug
shown
potentiali
nt
reat
parkinson
diseas
diabet
viral
microbi
infect
well
variou
cancerss
uch
divers
pharmacolog
activ
ar
esult
niclosamid
abil
uncoupl
mitochondri
phosphoryl
modul
elect
signal
pathway
wntbcatenin
mtor
implic
mani
diseas
highlight
discusst
plethora
diseas
niclosamid
shown
promis
treat
gether
studi
highlightst
neuroprotect
promis
niclosamid
may
hold
furtheri
nv
ivo
studi
pd
modelsar
need
establish
abil
niclosamid
treat
diseas
niclosamid
ethanolamin
salt
form
niclosamid
w
hich
exhibit
improv
aqueou
solubl
w
shown
improv
symptom
mice
inde
niclosamid
treatment
mice
fed
ah
ighfat
diet
led
improv
metabol
increas
lipid
oxid
high
energi
expenditur
addit
ndbdb
mice
wherein
diabet
induc
result
mutat
caus
defici
leptin
receptor
activ
n
iclosamid
ethanolaminew
shown
effect
improvingg
lycemicc
ontrol
treat
hyperglycemia
nd
slow
progress
diseas
ubsequ
tudi
n
iclosamid
piperazin
anoth
salt
form
niclosamid
also
found
similar
efficacyi
nt
reat
suggest
niclosamid
antidiabet
therapeut
potenti
duet
ot
inhibit
glucagon
signal
pka
pathway
niclosamid
also
shown
antimicrobi
activ
variou
bacteri
infect
methicillinresist
staphylococcu
aureu
mrsa
tuberculosi
tb
anthrax
ad
rug
repurpos
studi
use
al
ibrari
fdaapprov
drug
niclosamid
found
specif
inhibitg
rowth
grampositiveb
acteria
display
trong
vivo
vitro
activ
mrsa
mic
mgml
find
show
niclosamid
effect
vancomycin
current
drug
choicef
treatingm
rsa
subsequ
niclosamid
investig
potenti
antimicrobi
surfacec
oat
deviceassoci
hospitalacquir
infect
highli
versatil
niclosamidebas
antimicrobi
coat
develop
shown
clear
exist
infect
prevent
biofilm
format
low
concentr
niclosamid
also
shown
signific
antituberculosi
tb
activ
mic
mgml
interestingli
n
iclosamid
exert
pharmacolog
activ
stationaryphas
tubercleb
acilli
multidrugresist
tuberculosi
howev
potentialt
oxicityt
om
ammalian
cell
note
niclosamid
use
mic
henc
topic
use
niclosamid
surfaceloc
tuberculosi
may
hold
bettert
herapeut
promis
furthermor
niclosamid
identifi
abl
significantli
protect
cell
anthraxl
ethal
toxin
well
lethal
factor
pseudomona
exotoxin
fusion
protein
diphtheria
toxin
low
micromolar
concentr
activ
link
obstruct
process
anthrax
toxin
intern
andd
irectli
link
endosom
acidif
viral
infect
niclosamid
suggestedf
potentialu
se
ab
roadspectrum
antivir
target
host
pathway
use
virus
infect
unlik
current
antivir
strategi
whicha
direct
pecif
viral
target
broad
antivir
activ
niclosamid
link
abil
neutral
endosom
ph
therebi
disrupt
phdepend
membran
fusion
requir
viral
entri
date
sever
studi
indic
potentialu
se
niclosamid
treat
coronavirus
sarscov
chikungunya
viru
zika
ebola
virus
niclosamid
discoveredt
ob
ea
ble
inhibit
arscov
replic
low
micromolar
concentr
viral
antigen
synthesi
total
abolish
iclosamidec
oncentr
low
mm
exact
mode
action
clear
b
ut
niclosamid
found
interferew
ith
virion
attach
entri
cell
still
activ
even
ad
three
hour
viral
infect
cell
silico
studi
suggest
potenti
bind
niclosamid
sarscov
main
proteinas
howev
nli
modesta
ctiviti
niclosamid
proteinas
report
ic
mm
moreov
n
iclosamid
exhibiteda
ntivir
activ
chikungunya
viru
chikv
use
ac
hikv
nsect
cell
fusion
screen
assay
abl
inhibit
viru
entri
celltocel
transmiss
chikv
infect
light
recent
outbreak
zika
ebola
infect
focu
drug
repurpos
screen
fdaapprov
drug
rapid
identif
potenti
therapeut
agent
meet
urgentm
edic
need
treat
infect
use
approach
niclosamid
wasi
dentifi
inhibitor
zika
viru
valid
assay
confirm
abil
niclosamid
significantli
decreas
zika
rna
level
and
uppress
product
infecti
zika
particl
submicromolar
concentr
subsequ
niclosamid
emerg
ap
osit
hit
anoth
drug
repurpos
creen
aim
identifi
clinic
use
agentst
hat
may
activ
ebola
viru
ec
mm
diseas
receiv
far
attent
repurpos
niclosamid
cancer
date
niclosamid
shown
exhibit
anticanc
activitya
gainst
colon
breast
prostat
glioblastoma
osteosarcoma
ovarian
leukemia
adrenocort
carcinoma
lung
oral
cancer
observ
anticanc
activ
link
niclosamidesa
biliti
damag
tumor
cell
mitochondria
induc
apoptosi
inhibitt
umor
cell
prolifer
inhibitv
ariou
aberrantt
umor
signal
pathway
includ
wntbcatenin
nuclear
factorkb
nfkb
andn
otch
pathway
reviewedi
nd
etail
moskaleva
et
al
addit
broadspectrum
anticanc
activ
n
iclosamid
also
shown
inhibit
cancer
stem
cell
consid
attract
promis
anticanc
therapeut
target
accumulating
videnc
establish
crucial
role
cancer
chemmedchem
chemmedchem
chemmedchem
wwwchemmedchemorg
wileyvch
verlag
gmbh
co
kgaa
weinheim
initi
progress
establish
recurr
drug
resist
beyond
use
ingl
agent
niclosamid
studi
combin
convent
chemotherapeut
agent
instanc
combin
niclosamid
cisplatin
led
inhibit
cisplatinresist
tripleneg
breast
cancer
exhibit
synergist
effect
cisplatinresist
lung
cancerc
ell
enhanc
sensitivityo
f
chronic
myeloid
leukemia
cell
dasatinib
cervic
cancer
cell
paclitaxel
also
achiev
drug
use
combinationw
ith
niclosamid
ynergist
effect
erlotinib
colon
cancer
head
neck
cancer
erlotinibresist
nonsmall
ung
cancer
cell
also
describ
combin
niclosamid
bicalutamidel
ed
overcom
enzalutamideand
bicalutamideresist
prostat
cancer
combin
abirateron
found
effect
treat
advancedc
astrationresist
prostatec
ancer
furthermor
use
niclosamid
conjunct
radiotherapi
result
signific
radiosensit
effect
tripleneg
breast
cancer
cell
overcam
radioresist
lung
cancer
considerationsfor
use
niclosamidea
sa
therapeut
along
interest
repurpos
niclosamid
variousd
iseas
must
note
niclosamid
abil
influencem
signal
pathway
mayw
ork
disadvantag
would
lead
divers
side
effectsa
lso
favor
safeti
profil
niclosamid
treat
human
tapeworm
infect
could
due
fact
site
action
case
gut
henc
drug
absorb
modul
variou
signalingc
ascad
andc
aus
side
effect
newli
discov
diseas
niclosamid
may
herapeut
effect
system
deliveri
mayb
requir
henc
safeti
profil
niclosamid
case
still
larg
unknown
currenta
nd
futur
vivo
studi
niclosamid
provid
ac
learer
pictur
efficaci
toxic
determin
successo
ft
hese
repurpos
initi
niclosamid
shown
great
promis
treat
mani
diseas
uncoupl
oxid
phosphoryl
manipulationo
fv
ariou
cellsign
cascadesw
ith
safeti
concernsm
ay
aris
follow
system
exposur
insight
safeti
issu
attain
near
futur
variouso
ngo
clinic
investigationso
f
niclosamid
statement
st
ab
rief
highlight
niclosamid
pharmacolog
activ
imposs
includ
studi
publish
niclosamid
area
studi
discuss
work
ar
epres
sampl
myriad
niclosamid
therapeut
activ
